

## CURRICULUM VITAE

### Yun-Hee Kim, Ph.D.

#### Contact Information

Research Institute of National Cancer Center

Molecular Imaging & Therapy branch

323 Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do

410-769, Republic of Korea



Institution	Degree	Year(s)	Field
Kyunghee University, Seoul, Republic of Korea	B. S.	1989. 03 – 1994. 02	Biology
Yonsei University, Seoul, Republic of Korea (Advisor: Dr. Seung Soo Kim)	M.S.	1994. 09 – 1996. 08	Biochemistry, Cell biology
Pohang University of Science and Technology (POSTECH), Pohang, Republic of Korea (Advisor: Dr. Pann-Ghill Suh)	Ph.D.	2002. 03 – 2006. 02	Signal Transduction, Cell biology
POSTECH, Pohang, Republic of Korea	Post doctoral Fellow	2006. 03. – 2007.03	Signal Transduction, Cell biology,
Molecular Imaging & Therapy Branch, Research Institute of National Cancer Center	Senior Scientist	2007.04- 현재	1) Cancer Theragnostics (Aptamer, Ribozyme, Molecular Imaging, ) 2) Tumor microenvironment (pancreatic cancer metastasis)

#### Publication (recent 5 years)

**Kim YH<sup>+</sup>**, Kim KT, Lee SJ, Hong SH, Moon JY, Yoon EK, Kim S, Kim EO, Kang SH, Kim SK, Choi SI, Goh SH, Kim D, Lee SW, Ju MH, Jeong JS, Kim IH. Image-aided Suicide Gene Therapy Utilizing Multifunctional hTERT-targeting Adenovirus for Clinical Translation in Hepatocellular Carcinoma. *Theranostics* 2016;6:357-368

Heo K, Min SW, Sung HJ, Kim HG, Kim HJ, **Kim YH**, Choi BK, Han S, Chung S, Lee ES,

Chung J, Kim IH. An aptamer-antibody complex (oligobody) as a novel delivery platform for targeted cancer therapies. *J Control Release* 2016;229:1-9

Jun DW, Hwang M, **Kim YH**, Kim KT, Kim S, Lee CH. DDRI-9: a novel DNA damage response inhibitor that blocks mitotic progression. *Oncotarget*. 2016, *E-pub*

**Kim YH\***, Moon JY, Kim EO, Lee SJ, Kang SH, Kim SK, Heo K, Lee Y, Kim H, Kim KT, Kim D, Song MS, Lee SW, Lee Y, Koh SS, Kim IH. Efficient targeting and tumor retardation effect of pancreatic adenocarcinoma up-regulated factor (PAUF)-specific RNA replacement in pancreatic cancer mouse model. *Cancer Lett*. 2014;344(2):223-31

Yoon S<sup>+</sup>, **Kim YH**<sup>+</sup>, Kang SH, Kim SK, Lee HK, Kim H, Chung J, Kim IH. Bispecific Her2 × cotinine antibody in combination with cotinine-(histidine)<sub>2</sub>-iodine for the pre-targeting of Her2-positive breast cancer xenografts. *J Cancer Res Clin Oncol*. 2014 ;140(2):227-33

Sung HJ, Choi S, Lee JW, Ok CY, Bae YS, **Kim YH**, Lee W, Heo K, Kim IH. Inhibition of human neutrophil activity by an RNA aptamer bound to interleukin-8. *Biomaterials*. 2014 ;35(1):578-89

Kim JM, Choi JS, **Kim YH**, Jin SH, Lim S, Jang HJ, Kim KT, Ryu SH, Suh PG. An activator of the cAMP/PKA/CREB pathway promotes osteogenesis from human mesenchymal stem cells. *J Cell Physiol*. 2013 ;228(3):617-26

Kim JM, Kim J, **Kim YH**, Kim KT, Ryu SH, Lee TG, Suh PG. Comparative secretome analysis of human bone marrow-derived mesenchymal stem cells during osteogenesis. *J Cell Physiol*. 2013 ;228(1):216-24

Kyun H\*, **Kim YH\***, Sung HJ, Li HY, Yoo CW, Kim JY, Park JY, Lee U, Nam BH, Kim EO, Kim SY, Lee SH, Park JB, Choi SW. Hypoxia-induced up-regulation of apelin is associated with a poor prognosis in oral squamous cell carcinoma patients. *Oral Oncol*. 2012 ;48(6):500-6

Lee SJ, Kim SJ, Seo HH, Shin SP, Kim D, Park CS, Kim KT, **Kim YH**, Jeong JS, Kim IH. Over-expression of miR-145 enhances the effectiveness of HSVtk gene therapy for malignant glioma. *Cancer Lett*. 2012 ;320(1):72-80

Kim JM, Shin HI, Cha SS, Lee CS, Hong BS, Lim S, Jang HJ, Kim J, Yang YR, **Kim YH**, Yun S, Rijal G, Lee-Kwon W, Seo JK, Gho YS, Ryu SH, Hur EM, Suh PG. DJ-1 promotes angiogenesis and osteogenesis by activating FGF receptor-1 signaling. *Nat Commun*. 2012;3:1296

Lim S, Jang HJ, Park EH, Kim JK, Kim JM, Kim EK, Yea K, **Kim YH**, Ryu SH, Suh PG.

Wedelolactone inhibits adipogenesis through the ERK pathway in human adipose tissue-derived mesenchymal stem cells. *J Cell Biochem.* 2012;113(11):3436-45

**Kim YH\***, Sung HJ, Kim S, Kim EO, Lee JW, Moon JY, Choi K, Jung JE, Lee Y, Koh SS, Rhee SG, Heo K, Kim IH. An RNA aptamer that specifically binds pancreatic adenocarcinoma up-regulated factor inhibits migration and growth of pancreatic cancer cells. *Cancer Letters* 2011;313:76-83

Kim H, Dae HM, Park C, Kim EO, Kim D, Kim IH, **Kim YH\***, Choi Y\*. A highly sensitive magnetite nanoparticle as a simple and rapid stem cell labelling agent for MRI tracking. *J. Material. Chem.* 2011;21:7742-7747

Lim S, Jang HJ, Kim JK, Kim JM, Park EH, YangJH, **Kim YH**, Yea K, Ryu SH, Suh PG. Ochratoxin A inhibits adipogenesis through the ERK-1 PPAR- $\gamma$  pathway in human adipose tissue-derived mesenchymal stem cells. *Stem cells and Develop.* 2011;20:415-426

#### <산업재산권>

- 1) 트랜스-스플라이싱 라이보자임 및 암치료 유전자를 포함하는 재조합 아데노바이러스 및 이의 용도 2014. 02.19 미국 특허 출원
- 2) 안전성 및 항암활성이 증가된 재조합 아데노바이러스 및 이의 용도 2014.08.06 국내등록
- 3) 인터루킨-8 앵타머 및 이의 용도 2014.10.31 국내등록
- 4) PAUF 특이적 앵타머 및 이를 포함하는 췌장암 치료용 조성물 2013.03.28 국내등록
- 5) 양전하성의 초상자성 산화철 나노입자, 이를 이용한 조영제 및 그 제조방법 2013.03.08 국내등록

#### <기술이전>

- 1) hTERT표적의 트랜스스플라이싱 라이보자임을 이용한 간암 유전자 치료제 개발 2013.12. 보령계약 (300,000 천원)
- 2) HGF의 중화가능 에피토프 및 이에 결합하는 중화항체 노하우 개발 2014.05 아이바이오 (100,000 천원)